文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

抑制TREM-1与eCIRP相互作用减轻肝脏缺血再灌注损伤炎症并改善生存

Inhibition of the Interaction of TREM-1 and eCIRP Attenuates Inflammation and Improves Survival in Hepatic Ischemia/Reperfusion.
PubMed 文献 · Shock · 2022-01-01
一句话结论小鼠肝脏缺血再灌注模型中,TREM-1基因敲除或M3肽抑制TREM-1与eCIRP相互作用可减轻肝损伤与炎症,并将生存率从42%提高至75%。

该研究在野生型C57BL/6与TREM-1-/-小鼠中建立60分钟70%肝脏缺血、再灌注24小时的模型,并在再灌注开始时给予M3肽(10 mg/kg体重)或生理盐水对照。结果显示,TREM-1-/-小鼠与M3治疗组均显著降低血清肝损伤标志物(AST、ALT、LDH)、IL-6及组织学评分,并减轻中性粒细胞浸润(MPO、MIP-2、COX-2)与凋亡。生存手术中M3治疗将生存率从42%提高至75%。作者认为TREM-1是肝脏缺血再灌注炎症反应中重要的eCIRP受体,抑制TREM-1与eCIRP相互作用可能具有重要治疗潜力。

要点

  • 小鼠肝脏缺血再灌注模型中,TREM-1-/-小鼠较野生型I/R小鼠血清AST、ALT、LDH及IL-6水平与组织学评分显著降低。
  • TREM-1-/-小鼠中性粒细胞浸润标志物(MPO)及局部炎症标志物(MIP-2、COX-2)较野生型I/R小鼠减轻。
  • 再灌注开始时给予M3肽(10 mg/kg体重)可显著降低肝损伤与炎症标志物,并减少凋亡。
  • M3治疗使肝脏缺血再灌注后生存率从42%提高至75%。
  • 作者认为,抑制TREM-1与eCIRP相互作用在肝脏缺血再灌注中可能具有重要治疗潜力。

适用人群与场景

  • 野生型C57BL/6与TREM-1-/-小鼠,接受60分钟70%肝脏缺血及24小时再灌注。
  • 生存手术组小鼠在肝脏缺血再灌注基础上另行切除未缺血肝叶,并监测生存10天。

处置流程与药物剂量

  • 再灌注开始时给予M3肽10 mg/kg体重,或给予对照生理盐水。
  • 生存手术:小鼠在肝脏缺血再灌注后切除未缺血肝叶,监测生存10天。

研究设计与关键结果

  • 研究类型为小鼠在体实验;野生型I/R小鼠血清AST、ALT、LDH及IL-6升高、HE组织学评分升高,TREM-1-/-小鼠这些标志物显著降低。
  • TREM-1-/-小鼠中性粒细胞浸润标志物MPO及局部炎症标志物MIP-2、COX-2较野生型I/R小鼠减轻。
  • M3肽(10 mg/kg体重)治疗组肝损伤与炎症标志物较对照显著降低,并显示凋亡减少。
  • M3治疗使肝脏缺血再灌注后生存率从42%提高至75%。

证据类型、等级与局限

  • 证据类型:小鼠在体实验(基因敲除与肽抑制干预)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,抑制TREM-1与eCIRP相互作用在肝脏缺血再灌注中可能具有重要治疗潜力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Triggering receptor expressed on myeloid cells-1 (TREM-1) has important implications in sepsis and inflammation and is a novel receptor for extracellular cold-inducible RNA-binding protein (eCIRP). We hypothesize that the inhibition of TREM-1 via its interaction with eCIRP by novel peptide inhibitor M3 or knockout gene will attenuate the inflammation and injury associated with severe hepatic ischemia/reperfusion (I/R).

METHODS: Wild-type (WT) C57BL/6 and TREM-1-/- mice underwent 60 min of 70% hepatic ischemia, with 24 h of reperfusion. Additionally, WT mice underwent hepatic I/R and were treated with M3 (10 mg/kg body weight) or vehicle (normal saline) at the start of reperfusion. Blood and ischemic liver tissues were collected, and analysis was performed using enzymatic assays, enzyme-linked immunosorbent assay, reverse-transcription quantitative polymerase chain reaction, and pathohistology techniques. For survival surgery, mice additionally underwent resection of non-ischemic lobes of the liver and survival was monitored for 10 days.

RESULTS: There was an increase in serum levels of tissue markers including aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase as well as cytokine levels (IL-6) and histological scoring of hematoxylin and eosin sections in WT I/R mice. These markers decreased substantially in TREM-1-/- mice. Additionally, neutrophil infiltration markers and markers of local inflammation (myeloperoxidase, macrophage inflammatory protein-2, cyclooxygenase-2) were attenuated in TREM-1-/- mice. Similarly, we show a significant decrease in injury and inflammation markers with M3 treatment. Additionally, we demonstrate decreased apoptosis with TREM-1 inhibition. Finally, M3 treatment improved the survival rate from 42% to 75% after hepatic I/R.

CONCLUSION: TREM-1 is an important eCIRP receptor in the inflammatory response of hepatic I/R, and deficiency of TREM-1 via knockout gene or peptide inhibition attenuated liver injury and inflammation, and improved survival. Inhibition of the TREM-1 and eCIRP interaction in hepatic I/R may have important therapeutic potential.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Borjas T, Jacob A, Yen H, et al. Inhibition of the Interaction of TREM-1 and eCIRP Attenuates Inflammation and Improves Survival in Hepatic Ischemia/Reperfusion. Shock. 2022. PMID: 34864782. doi:10.1097/SHK.0000000000001894

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。